ESALF News and Press, Eisai Co Ltd From 05/15/23

2023-05-15 12:35:17 ET Eisai press release ( OTCPK:ESALF ): FY GAAP EPS of ¥193.31. Revenue of ¥744.4B (-1.6% Y/Y). For further details see: Eisai GAAP EPS of ¥193.31, revenue of ¥744.4B

2023-05-14 14:20:00 ET Summary Bliss Biopharma (Hangzhou) announced it may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Shanghai Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to...

2023-05-11 05:56:21 ET The U.S. Food and Drug Administration (FDA) approved the expanded use of H. Lundbeck ( OTCPK:HLBBF ) ( OTCPK:HLUBF ) and Otsuka's ( OTCPK:OTSKY ) ( OTCPK:OTSKF ) medicine Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzh...

2023-05-06 01:58:52 ET Summary Like other anti-amyloid drugs, Eli Lilly's donanemab does not help APOE4 non-carriers. Donanemab does modestly slow down the progression of Alzheimer's disease during its early stages in APOE4 carriers but can cause brain bleeds and brain swelling, w...

2023-05-03 22:35:00 ET Summary Eli Lilly made headlines this morning with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial. The natural comparison is with lecanemab (Leqembi), the recently approved antibody from Eisai and B...

2023-05-03 15:37:28 ET Eli Lilly ( NYSE: LLY ) added ~7% to reach a new 52-week high Wednesday after the company reported early Phase 3 data for its anti-amyloid agent donanemab in Alzheimer's disease, sparking sharp gains among rival drug developers. Notable gainers include...

2023-05-01 08:47:05 ET After three straight sessions of gains, Biogen ( NASDAQ: BIIB ) shares continued to rise in the pre-market Monday as Guggenheim upgraded the biotech citing full FDA approval for its Alzheimer's therapy Leqembi developed with Eisai ( OTCPK:ESALF )( OTCPK:...

2023-04-26 11:32:44 ET Eli Lilly ( NYSE: LLY ) is expected to report its Q1 2023 results before the opening bell on Thursday for a market on the lookout for updates on its pipeline led by Alzheimer’s candidate donanemab and weight loss agent tirzepatide. Amid waning deman...

2023-04-25 08:01:00 ET Biogen ( NASDAQ: BIIB ) stock is trading in the red premarket Tuesday after the company said it is discontinuing certain drug programs amid reporting its Q1 results, which beat estimates. Biogen said it will terminate its involvement in developing BI...

2023-04-06 12:35:54 ET FDA’s accelerated drug approval program came under scrutiny on Thursday after the agency withdrew its approval for Makena, a drug first cleared the regulatory hurdle more than a decade ago to prevent preterm birth in women. The FDA approved Makena in 2011 u...